Utilizing CAR T-Cell Therapy in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Wrapping up their discussion, Loretta J. Nastoupil, MD, and Marc S. Hoffman, MD, look at the use of CAR T-cell therapy for patients with mantle cell lymphoma, a rare subtype of non-Hodgkin’s lymphoma.

Related Videos
Jeffery Zonder, MD
Jeffery Zonder, MD
Abhinav Deol, MD
Veronika Bachanova, MD, PhD
Eunice Wang, MD
Craig Sauter, MD
Lisa A. Carey MD, ScM, FASCO
Patrick I. Borgen, MD
Anees Chagpar, MD, MBA, MPH, FACS, FRCS(C)
Steven J. Chmura, MD, PhD
Related Content

New Model Predicts Long-term Response to CAR T-cell Therapy in B-cell Lymphoma

March 24th 2023

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

October 10th 2022

Second-line Axi-cel Elicits OS Benefit in Relapsed/Refractory LBCL

March 21st 2023

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

July 28th 2022

Siltuximab Resolves CRS/ICANS After CAR T-cell Therapy for Hematologic Malignancies

March 16th 2023

Bispecific CD20/CD19-targeted CAR T-cell Therapies May Improve Outcomes in MCL

March 15th 2023

New Model Predicts Long-term Response to CAR T-cell Therapy in B-cell Lymphoma

March 24th 2023

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

October 10th 2022

Second-line Axi-cel Elicits OS Benefit in Relapsed/Refractory LBCL

March 21st 2023

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

July 28th 2022

Siltuximab Resolves CRS/ICANS After CAR T-cell Therapy for Hematologic Malignancies

March 16th 2023

Bispecific CD20/CD19-targeted CAR T-cell Therapies May Improve Outcomes in MCL

March 15th 2023

New Model Predicts Long-term Response to CAR T-cell Therapy in B-cell Lymphoma

March 24th 2023

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

October 10th 2022

Second-line Axi-cel Elicits OS Benefit in Relapsed/Refractory LBCL

March 21st 2023

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

July 28th 2022

Siltuximab Resolves CRS/ICANS After CAR T-cell Therapy for Hematologic Malignancies

March 16th 2023

Bispecific CD20/CD19-targeted CAR T-cell Therapies May Improve Outcomes in MCL

March 15th 2023